IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSidney Kimmel Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesSidney Kimmel Cancer Center
Inactive CompaniesN/A
Active IndicationsGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A